-
Official opening of new Oncolines home, the Marie Curie Building at the Pivot Park in Oss, The Netherlands
After months of dedication and collaboration, the official opening of the Marie Curie building at the Pivot Park in Oss was opened on Sep 19th, 2024. The Marie Curie building is a multitenant laboratory building which houses Oncolines B.V., the in vitro biology services laboratory of Symeres. Read more about this exciting development!
-
J. Med. Chem. Publication: Preclinical Lead Optimization of a 1,2,4-Triazole-Based Tankyrase Inhibitor
In collaboration with Oslo University Hospital, we report the synthesis and biological activity of novel 1,2,3-triazole-based tankyrase inhibitors. Through a modular synthetic pathway and X-ray crystallography supported SAR analysis, we synthesized a series of novel TNKS inhibitors with improved ADME profiles, exhibiting antiproliferative efficacy in colorectal cancer cell lines. Click on the link below for a short summary of this publication.
-
New video of our Solid-State Center of Excellence
In this new video our colleagues Gabriella Pizutti, Chantalle van Berkel, and Eva Verhofstad, will give you an exciting lab tour through the Symeres Solid-State Centre of Excellence, located at the Symeres site in Weert, the Netherlands. You will learn more about PhysChem Properties, Solid Form Screening, Crystallization, Crystal Habit, Pre-formulation, and Formulation. Feel free to contact us via the contact form on this website if you would like to learn more about our Solid-State capabilities.
-
Marina Virgili about Barcelona and Groningen
We had the pleasure of sitting down with Marina Virgili, a dynamic and accomplished professional with a fascinating history in the pharmaceutical industry. Originally from the beautiful city of Barcelona, Marina shared insights into her background, career, and the unique experiences she has encountered along the way.
-
New equipment at Exemplify
Exemplify has recently acquired a Mettler-Toledo EasyMax 402 automated reactor system to add to its process development capabilities. This instrument can accommodate reactor sizes of 100 and 400 mL and allows for the precise automated control of reaction parameters such as temperature, stirring speed, reagent addition rate, and pH, providing real-time data collection that can greatly enhance our understanding of a reaction’s unique profile.
-
New 100 L vessels in Groningen
The first of the two new 100 L glass-lined stainless steel reactor lines has successfully finished the testing and now it is operational at our Groningen site. By doubling our batch size capacity, we have increased the efficiency for large-scale non-GMP production projects. This will result in faster delivery times for our clients and less batch routine work for our chemists.
-
Rory Curtis joins Symeres Business Development Team
We are happy to have such an experienced biologist on board to work with our many American clients. In this interview, our new colleague, Rory Curtis, will introduce himself and talk about the journey that led him from London to the city of Buffalo in New York state.
-
Symeres CEO Eelco Ebbers Speaks on “Leaders in Life Sciences” Podcast
Symeres CEO Eelco Ebbers recently shared his insights on the renowned “Leaders in Life Sciences” podcast, hosted by Henk Jan Out. Recorded at the Pivot Park in Oss, near our subsidiary Oncolines, the interview delved into various facets of Eelco’s journey, including his educational background in organic chemistry, Symeres’ services and strategy, as well as personal interests such as family and hobbies.
-
Organix: New facility
On March 26th we had the Grand Opening of our brand new, state-of-the-art Organix synthetic and analytical chemistry laboratories in Woburn, just outside Boston MA.
-
Towards Multitargeted Ligands as Pain Therapeutics: Dual Ligands of the Cavα2δ-1 Subunit of Voltage-Gated Calcium Channel and the μ-Opioid Receptor
In collaboration with WeLab Barcelona, we report the synthesis and biological activity of novel pain therapeutics, which target both Cavα2δ-1 and MOR. One of these disubstituted pyrrolidines demonstrated an analgesic effect in various rodent models of pain, and a lack of unfavorable off-target interactions, showing no evident signs of withdrawal or tolerance. Click on the link below for a short summary of this publication.
-
Innovative macrocycles as powerful Mcl-1 inhibitors
This is a recap of the article “Development of potent Mcl-1 inhibitors: structural investigations on macrocycles originating from a DNA-encoded chemical library screen” published in the Journal of Medicinal Chemistry. Myeloid cell leukemia 1 (Mcl-1) is a protein that plays a crucial role in the regulation of cell survival and cell death. It is part of a family of proteins called the Bcl-2 family, which are known for their involvement in controlling the life span of cells.
-
Oncolines unveils new State-of-the-Art Laboratories
In a significant stride towards advancing cancer research and drug development, Oncolines, has officially received the keys to its new laboratories and offices situated within the prestigious Curie Building on the Pivot Park in Oss, the Netherlands.
Feel free to contact us!
Curious to know more about what can we do for you? Get in touch and let’s start a conversation.
